Chimerix Investor Conference Presentation Deck
Integrated Efficacy Analysis: Objective and Eligibility Criteria
Objective
To evaluate monotherapy efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma
Eligibility
●
●
●
Washouts prior to first ONC201 dose:
Radiation: 90 days
Temozolomide: 23 days / Antibodies (e.g., bevacizumab): 42 days / Other anticancer therapies: 28 days
● Baseline Performance Status 260
●
Age 22yo and received ONC201 under studies ONC006, ONC013, ONC014, ONC016, or ONC018
Diffuse glioma with a known H3K27M mutation and involvement of a midline structure of the brain
Progressive and measurable disease on contrast-enhanced brain MRI by RANO-High Grade Glioma (HGG) criteria
Prior therapy with at least radiation
●
Corticosteroids stable or decreasing for at least 3 days prior to baseline scan
Excluded: DIPG, primary spinal tumors, atypical and non-astrocytic histologies, leptomeningeal spread, CSF disseminationView entire presentation